Creso inks commercial deal for cannaQIX® in Benelux region

By Zoe Gross. Published at May 21, 2018, in Biotech

ASX pot-stock, Creso Pharma (ASX:CPH), has clinched a commercial agreement with Dutch company, Mediphos OTC Consumer Health BV, to market and distribute its CBD hemp-based human health nutraceutical product, cannaQIX®, in the Benelux region — Belgium, the Netherlands and Luxembourg.

The first purchase order has already been placed.

This agreement follows on from the successful, revenue-generating launch of cannaQIX® in Switzerland and Lichtenstein, and a pending launch in the UK.

cannaQIX® is the first standardised nutraceutical containing organic hemp extract with cannabidiol (CBD), vitamins and zinc, developed to reduce stress and support mental and nervous system functions.

The launch and distribution of cannaQIX® in the Netherlands is planned for the third quarter of the year.

CPH has obtained the relevant approvals to market cannaQIX® by KOAG/KAG, the Dutch Council for monitoring of health products in the Netherlands.

CPH is tapping a fertile market here. The over-the-counter (OTC) market in the Netherlands reached €789 million in 2016 and is growing at 5 per cent per year. Food supplements like cannaQIX® make up around 20 per cent of these sales.

However, the size of the market share CPH can secure remains to be seen at this stage, so if considering this stock for your portfolio, do your own research and seek professional financial advice.

CPH CEO and co-founder, Dr. Miri Halperin Wernli, said: “We are really excited to enter the Benelux countries with Mediphos OTC Consumer Health, which is a young, flexible and innovative company. There is a great fit with Creso Pharma and we anticipate a very successful collaboration and commercialisation of cannaQIX® in the Benelux.”

Mediphos CEO and founder, Andre van der Mark, commented: “We are looking forward to partnering with Creso Pharma, and have already placed our first order with them. Creso Pharma is known for its high quality, pharma grade innovative products like cannaQIX. It is a good fit for the portfolio strategy of Mediphos OTC Consumer Health, with brands positioned in carefully selected niche markets and categories for consumers treating minor ailments.”

More on cannaQIX®

The cannaQIX® range of products are CBD hemp-based nutraceuticals, using CPH’s proprietary innovative delivery technology. These products contain full-spectrum organic hemp extract with CBD, vitamins and zinc, aiming to reduce stress and to support mental and nervous functions.

Creso pharma cannaqix

The proprietary QIX technology-based delivery system contains capsicum, which accelerates blood circulation in the mouth, enhancing the buccal sublingual delivery of the CBD, vitamins and zinc into the bloodstream.

cannaQIX®, is safe, well-tolerated, non-psychoactive, non-addictive and sugar-free. The standardised, user-friendly strength and formulation allows precise dosage control, ensuring a reliable and stable effect over several days.

cannaQIX®, is produced in Switzerland in a Good Manufacturing Practice (GMP) certified facility by CPH’s partner, Swiss-based food and pharma development company, Domaco, Dr. med Aufdermaur AG (Domaco), to the highest Swiss quality and with a “Swiss made” label.

With this product, CPH is offering a safe, effective food supplement with broad access and over-the-counter availability.


S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.

Facebook
Twitter
LinkedIn